ESSA Pharma Inc (EPIX)

[davidsson10]

$5 = A Good Feeling

[BoilerRoom]

$EPIX Weeeeeeeeeeeeee!!

[MiamiGent]

EPIX Here comes another. We aren't dead yet :)

EPIX ESSA PHARMA INC
$4.33 +2.61 (+151.76%)
As of Oct-26-2022 12:46:58 PM ET

https://stockcharts.com/h-sc/ui?s=EPIX

Updated Results From The Phase 1/2 Study Of ESSA's Lead Candidate EPI-7386 In Combination With Enzalutamide Highlighted At The 29th Annual Prostate Cancer Foundation Scientific Retreat

By Benzinga — 7:10 AM ET 10/26/22
EPI-7386 in combination with enzalutamide was safe and well-tolerated at the doses tested with clinically relevant drug exposures and deep and durable prostate specific antigen ("PSA") reductions observed in five of six patients

Updated Results from the Phase 1/2 Study of ESSA’s Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat
http://archive.fast-edgar.com/20221026/AHZZK62CZ22BMZZ2222G2ZZZMBB9ZZTSEW42/ex991.htm

Company Profile
Sector Health Care
Industry Biotechnology
Company Location Vancouver, BC

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

[BoilerRoom]

Nice find bro just bought chit load

[Frankestin]

Wow
I took the order at 3.77
50% gone
I keep the rest

[Invest-in-America]

EPIX: The obvious WINNER stock run of this day, but only a few posts on its iHub Board --- & mostly by just one Guy!! And CONGRATS to YOU, Dude!!!

[KOmani]

Shorts trying their best.

Not really sure I would risk it when a $4 million buy order comes across mid-day on a stock like this.

[Frankestin]

IMO it is very likely to shoot for a few days ...
It seems to me that the study with Bayer has to start
then there's that new agent

[Frankestin]

not to forget, someone liquid knows things first
https://finance.yahoo.com/news/epix-45-million-financing-includes-132200281.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAALg15cZWaXfx8YX3WUXfKt1Ap7rgt7pcJxQX8BopggAAD3-DNMv66pRg31833x3kVV3BSqCpoxbGEDVOVD7Hcj2e7c0lg_5wmvotdftG20G8sg2X5tXl8AxMdWryVrA00lSU_XJXlriwOLTjl8qYcWUYpBH11X-G5gYzmYeNeJuH

[Frankestin]

Insider Ownership 21.93% (purged 10/14%)
Institutional Shares (Long) - 95.17% (ex 13D/G)

Istitutions 77%
Found 29,69%

[Frankestin]

MC 90/100 mil
cash $174.6M reported at June 30, 2022
Current cash runway through 2024 funds

3 Posters
Today announced the presentation of updated clinical data from the first two cohorts of the Phase 1/2 study of ESSA's lead candidate EPI-7386 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer ("mCRPC"). Data will be presented in a poster format at the 2022 Prostate Cancer Foundation ("PCF") Scientific Retreat, taking place October 27-29, 2022 in Carlsbad, CA.

The safety of the combination was favorable with a safety profile consistent with second-generation antiandrogens and no dose limiting toxicities observed.

Two additional posters will be presented at the conference highlighting updated results from the first-in-human Phase 1a dose escalation study of EPI-7386 as a monotherapy in mCRPC patients failing current second-generation antiandrogens and preclinical data on ESSA's first-in-class N-terminal domain androgen receptor protein degrader ("ANITAC"™) program.

[Frankestin]

2022-07-12 13G/A BIOTECHNOLOGY VALUE FUND L P 4,565,242 8,748,629 +91.64

[Frankestin]

https://www.marketbeat.com/stocks/NASDAQ/EPIX/institutional-ownership/

https://www.morningstar.com/stocks/xnas/epix/ownership
Found
Total (for Top 20) 33.21 14,630,814
Institution
Total (for Top 20) 79.50 35,025,554
Mmmm

[Frankestin]

I finished uploading 2.64 last purchase
fingers crossed... for after the summer
MC 77 mil

[Frankestin]

in TRIL, after entering, the stock sketch at 29/30, if I remember correctly, then someone started selling! I wonder who was interested? they bring it to 5 and then they did BO

if the studies give us good news...

someone buys
https://fintel.io/n/us/cbio

[catinhat]

I added more Friday and today. Science is playing out as expected at this point.

Not sure how all those shares short are going to get covered in a name that trades this thinly.

We get more buy side analysts that are discovering the name pitching it to their pm's, and the buying could create a pretty uncomfortable situation for the those needing to cover.

Volume on sell-off has been pretty light. The strong hands are not letting go. Pfizer and Janssen know what this trial data means for the science.

[Frankestin]

I add!
Shhhhhhhhh

[Frankestin]

https://fintel.io/so/us/epix
I am tempted to add, but I am waiting maybe they charge me $ 3 or even $ 2

[catinhat]

Combo (with Pfizer's enzalutamide) patients hit PSA90 (a 90% reduction in PSA levels) within 3 MONTHS. By comparison, in enzalutamide's mono trials less than half of patients attained PSA90. Pfizer already owns 4% of EPIX.

Early combo looks terrific. And the mono is doing what they expected, they KNOW they have to adjust trial to focus on AR-driven disease, and they've done that. So going forward mono is till clearly in the game. And combo could be crazy.

No volume on the open, nobody is selling. Strong hands. I'm showing 75% Institutional and 16.65% Insider, including Pfizer with 3.8%. Per Factset.

[Frankestin]

Go as you go, how can you not keep them?
Insider Ownership 21.93%
Institutional Shares (Long) - 96.63% (ex 13D/G)
MC $120M
At March 31, 2022, the Company had available cash reserves and short-term investments of $181.0 million reflecting the gross proceeds of the February 2021 financing of approximately $150.0 million and July 2020 financing of $48.9 million, less operating expenses in the intervening period. The Company's cash position is expected to be sufficient to fund current and planned operations through 2024.

[Frankestin]

ESSA PHARMA INC
EPI-7386 WAS SAFE AND WELL-TOLERATED AT ALL DOSE LEVELS
EPI-7386 SCHEDULES TESTED WITH PLASMA TARGET CONCENTRATIONS ACHIEVED AND CLINICALLY IMPORTANT EFFICACY SIGNALS
ESSA PHARMA INC - EXPECTS TO INITIATE PHASE 1B MONOTHERAPY EXPANSION STUDY IN Q3 2022

We are pleased with the progress in advancing our novel prostate cancer candidate EPI-7386 as a monotherapy in patients with advanced mCRPC.

We continue to be excited by our combination trials evaluating EPI-7386 with the four leading, commercially available antiandrogens in earlier line patient populations

I hope some huge portfolios get excited too...

[catinhat]

Yeah, he point blank said "by the end of June you will see everything that we have". And he emphasized "everything".

If they don't, not sure what that means. But he was VERY specific. I think you can go back and watch the Bloom Burton replay if still out there, I know I'm not crazy. :)

[Frankestin]

the study says August but if they say they will give advances in the second quarter ... here we are!

[catinhat]

Well, we've got 4 days to see some news.

They definitively said at Bloom Burton "you will see everything we have" (speakinng to monotherapy data).

Wish they would just get it over with at this point.

[Frankestin]

Monotherapy
Present clinical update on phase 1 trial. 1H 2022
Establish the recommended phase 2 dose (RP2D). 1H 2022
Initiate the expansion portion of phase 1 trial. 1H 2022
Combination
Initiate phase 1 portion of EPI-7386 combination trials with all partners. 1H 2022
https://clinicaltrials.gov/ct2/show/NCT05075577?cond=EPI-7386&draw=2&rank=1
https://clinicaltrials.gov/ct2/show/NCT04421222?cond=EPI-7386&draw=2&rank=2
https://clinicaltrials.gov/ct2/show/NCT05295927?cond=EPI-7386&draw=2&rank=3

[Frankestin]

I invested in the pu..y but it does not pay, see OBSV!
I fear some sexist conspiracy
I hope the d..k pays more! So Epix!
let's wait

[catinhat]

I've been hearing that the monotherapy data coming this month is less than exciting, and the bigger event will be combination therapy data, which we are 6-12 months away from.

In the meantime, it seems the spreading of this expectation for mediocre monotherapy data has driven short interest through the roof. Hate to say it, but I'm expecting a sharp sell off on the data release. Will likely buy into that drop, unless something concerning in the data.

[Frankestin]

https://wsw.com/webcast/jeff240/epix/1855350
will there be something new?
https://filecache.investorroom.com/mr5ircnw_essapharma/303/ESSA%20Corporate%20Presentation_March%202022.pdf

[Frankestin]

The Company expects to provide a clinical update on the Phase 1a dose escalation study in the first half of 2022.
Give us good results!

[Frankestin]

https://www.tipranks.com/experts/analysts/prasath-pandurangan?ref=MCO_EXPERT
Bloom Burton bean

[Frankestin]

took a handful!
in the middle of the year it seems to me that results are expected and at these prices ...

[catinhat]

Welcome to the EPIX board, would love to know who else has followed the stock, long or short, and what your thoughts are. Disclosure: I've owned the stock for about five years, traded around a bit but always long and have grown my position.

Much to discuss: next up is monotherapy data ("you'll see everything we have", CEO during Bloom Burton conference recently), and then the bigger and more exciting driver, combination therapy progress and results.

Will leave it at that for now, let's discuss!